Research & Development

Can Novartis and Baiyu Revolutionize Cancer Treatment Together?
Research & Development Can Novartis and Baiyu Revolutionize Cancer Treatment Together?

In a bold move that underscores its commitment to advancing cancer therapies, Novartis has taken a significant step by investing $70 million upfront in Chengdu Baiyu Pharmaceutical for global rights to a small molecule cancer treatment. This partnership is accompanied by potential milestone

How Will Nuclera's New Funding Revolutionize Drug Discovery?
Research & Development How Will Nuclera's New Funding Revolutionize Drug Discovery?

Nuclera, a trailblazing biotechnology company specializing in protein expression and purification, recently raised $75 million in a fresh funding round. This significant financial boost is intended to support the commercialization and global deployment of Nuclera’s eProtein Discovery™ system. The gr

Can RNA Editing Revolutionize Genetic Therapy for AATD Patients?
Research & Development Can RNA Editing Revolutionize Genetic Therapy for AATD Patients?

RNA editing has long been a topic of fascination within the field of genetic research. Recent advancements by Wave Life Sciences have transformed this curiosity into a real-world application, with their trials showing promising results for treating alpha-1 antitrypsin deficiency (AATD). This

Can Ellorarxine Transform ALS Treatment and Neurodegenerative Care?
Research & Development Can Ellorarxine Transform ALS Treatment and Neurodegenerative Care?

Ellorarxine, a groundbreaking drug compound developed by Nevrargenics, is showing remarkable promise in the treatment of Amyotrophic Lateral Sclerosis (ALS) and has recently received approval from the MHRA to advance to human trials. This news brings a glimmer of hope to the over 5,000 individuals

How Does Proper COA Selection Influence Drug Development Success?
Research & Development How Does Proper COA Selection Influence Drug Development Success?

Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes

Lundbeck Acquires Longboard for $2.6B to Boost Neurology Portfolio
Research & Development Lundbeck Acquires Longboard for $2.6B to Boost Neurology Portfolio

Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later